MA42302A - Lactames bicycliques et leurs méthodes d'utilisation - Google Patents

Lactames bicycliques et leurs méthodes d'utilisation

Info

Publication number
MA42302A
MA42302A MA042302A MA42302A MA42302A MA 42302 A MA42302 A MA 42302A MA 042302 A MA042302 A MA 042302A MA 42302 A MA42302 A MA 42302A MA 42302 A MA42302 A MA 42302A
Authority
MA
Morocco
Prior art keywords
milks
bicyclic
methods
bicyclic milks
Prior art date
Application number
MA042302A
Other languages
English (en)
Inventor
Huifen Chen
Gregory Hamilton
Snahel Patel
Craig Stivala
Guiling Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA42302A publication Critical patent/MA42302A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA042302A 2015-07-02 2016-07-01 Lactames bicycliques et leurs méthodes d'utilisation MA42302A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188153P 2015-07-02 2015-07-02
US201562387295P 2015-12-23 2015-12-23

Publications (1)

Publication Number Publication Date
MA42302A true MA42302A (fr) 2018-05-09

Family

ID=56411952

Family Applications (2)

Application Number Title Priority Date Filing Date
MA042302A MA42302A (fr) 2015-07-02 2016-07-01 Lactames bicycliques et leurs méthodes d'utilisation
MA053835A MA53835A (fr) 2015-07-02 2016-07-01 Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA053835A MA53835A (fr) 2015-07-02 2016-07-01 Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires

Country Status (24)

Country Link
US (2) US10988459B2 (fr)
EP (2) EP3317269B1 (fr)
JP (2) JP6785252B2 (fr)
KR (2) KR102603915B1 (fr)
CN (3) CN112979660A (fr)
AU (4) AU2016287581B2 (fr)
CA (2) CA2988601C (fr)
CL (2) CL2017003486A1 (fr)
CO (1) CO2017013709A2 (fr)
CR (1) CR20170573A (fr)
ES (1) ES2930749T3 (fr)
IL (2) IL255830B (fr)
MA (2) MA42302A (fr)
MX (2) MX380753B (fr)
MY (1) MY192762A (fr)
PE (2) PE20180501A1 (fr)
PH (1) PH12018500034A1 (fr)
PL (1) PL3317269T3 (fr)
RU (1) RU2716136C2 (fr)
SG (1) SG10201913880XA (fr)
TW (2) TWI788830B (fr)
UA (1) UA122150C2 (fr)
WO (1) WO2017004500A1 (fr)
ZA (1) ZA201707812B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2716136C2 (ru) 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
WO2017069279A1 (fr) * 2015-10-23 2017-04-27 武田薬品工業株式会社 Composé hétérocyclique
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
US9815850B2 (en) * 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
JP7349359B2 (ja) * 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
US11072607B2 (en) * 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3585782A1 (fr) 2017-02-27 2020-01-01 GlaxoSmithKline Intellectual Property Development Limited Amides hétérocycliques en tant qu'inhibiteurs de kinase
GB201706102D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200737B (zh) * 2017-06-29 2019-03-26 武汉药明康德新药开发有限公司 叔丁氧羰基-3-(羟甲基)-[1,2,3]三氮唑[1,5-a]哌啶-6-酰胺制法
CN119613408A (zh) 2017-07-14 2025-03-14 豪夫迈·罗氏有限公司 二环酮化合物及其使用方法
WO2019072942A1 (fr) * 2017-10-11 2019-04-18 F. Hoffmann-La Roche Ag Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1
MX2020003451A (es) * 2017-10-31 2020-08-03 Hoffmann La Roche Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos.
EP3781571B1 (fr) 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG Dérivés de n-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide et composés similaires en tant qu'inhibiteurs de la kinase rip1 pour le traitement p.e. du syndrome de l'intestin irritable (sii)
PL3788045T3 (pl) 2018-05-03 2023-10-09 Rigel Pharmaceuticals, Inc. Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
SI3788044T1 (sl) 2018-05-03 2023-12-29 Rigel Pharmaceuticals, Inc. Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo
CN110642874B (zh) * 2018-06-26 2023-03-28 中国科学院上海有机化学研究所 一类细胞坏死抑制剂及其制备方法和用途
WO2020001420A1 (fr) * 2018-06-26 2020-01-02 中国科学院上海有机化学研究所 Inhibiteur de nécrose cellulaire, son procédé de préparation et son utilisation
WO2020044206A1 (fr) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Amides hétérocycliques utiles en tant qu'inhibiteurs de kinases destinés à être utilisés dans le traitement du cancer
WO2020054657A1 (fr) * 2018-09-10 2020-03-19 科研製薬株式会社 Dérivé d'amide hétéroaromatique et médicament le contenant
CN109134448B (zh) * 2018-10-16 2020-11-27 中南大学湘雅医院 杂环化合物及其盐、制备方法、用途和药物
BR112021009610A2 (pt) 2018-11-20 2021-08-10 Sironax Ltd composto, composição farmacêutica, uso de um composto ou composição, e, método de inibir necrose, ferroptose, rip1 humana ou indicações relacionadas
CN113302193B (zh) * 2019-01-11 2026-05-29 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
CA3127701C (fr) * 2019-01-25 2023-08-15 Beijing Scitech-Mq Pharmaceuticals Limited Compose heterocyclique a pont acylamino, composition et utilisation associees
AR118243A1 (es) 2019-03-07 2021-09-22 Pi Industries Ltd Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas
CA3142360C (fr) * 2019-05-31 2023-11-14 Medshine Discovery Inc. Compose bicyclique en tant qu'inhibiteur de la kinase rip-1 et son application
CN110183442A (zh) * 2019-06-06 2019-08-30 无锡合全药业有限公司 一种1 -(乙氧羰基)咪唑并[1, 5]吡啶-6-羧酸的合成方法
ES3043457T3 (en) * 2019-09-06 2025-11-25 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
JP2022547882A (ja) * 2019-09-06 2022-11-16 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤
AU2020341708B2 (en) 2019-09-06 2024-01-04 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
US11718612B2 (en) 2019-09-06 2023-08-08 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
SMT202600151T1 (it) 2019-11-07 2026-05-12 Rigel Pharmaceuticals Inc Composti eterociclici inibitori di rip1
AU2020391425A1 (en) * 2019-11-26 2022-06-16 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease
KR20220118525A (ko) 2019-12-20 2022-08-25 화이자 인코포레이티드 벤즈이미다졸 유도체
BR112022017099A2 (pt) * 2020-02-28 2022-11-16 Univ Texas Composto, composição farmacêutica, método para inibição de ripk1, método para tratamento de uma doença mediada por ripk1 e método para tratamento de lesão no snc
JP7701162B2 (ja) * 2020-02-28 2025-07-01 科研製薬株式会社 新規ヘテロ芳香族アミド誘導体又はその塩からなる医薬
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
WO2021207308A1 (fr) 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Dérivés de pyrazole condensés utiles en tant qu'inhibiteurs de sarm1
WO2021233861A1 (fr) 2020-05-19 2021-11-25 Bayer Aktiengesellschaft (thio)amides azabicycliques en tant que composés fongicides
BR112022024413A2 (pt) 2020-06-10 2023-02-07 Bayer Ag Heterociclos substituídos com azabiciclila como fungicidas inovadores
TWI824259B (zh) 2020-07-01 2023-12-01 美商雷傑製藥公司 Rip1k抑制劑
EP3974414A1 (fr) 2020-09-25 2022-03-30 Bayer AG Pyrazoles et triazoles substitués par un 5-amino en tant que pesticides
WO2022171110A1 (fr) * 2021-02-10 2022-08-18 Zai Lab (Us) Llc Composés tricycliques fusionnés en tant qu'inhibiteurs de rip1-kinase et leurs utilisations
WO2022171111A1 (fr) * 2021-02-10 2022-08-18 Zai Lab (Us) Llc Composé bicyclique fusionné hétéroaryle utile en tant qu'inhibiteur de la rip1-kinase et ses utilisations
TW202300490A (zh) * 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
CA3214802A1 (fr) 2021-04-02 2022-10-06 Genentech, Inc. Procedes de fabrication de composes cetoniques bicycliques
CN115611731A (zh) * 2021-04-26 2023-01-17 成都伊诺达博医药科技有限公司 一种依洛昔巴特中间体的合成方法
CN113651810B (zh) * 2021-07-16 2023-10-13 上海毕得医药科技股份有限公司 一种3-甲酰基-1H-吡唑并[3,4-b]吡啶-5-羧酸甲酯的合成方法
TW202321211A (zh) 2021-08-10 2023-06-01 美商艾伯維有限公司 菸鹼醯胺ripk1抑制劑
WO2023020486A1 (fr) * 2021-08-17 2023-02-23 广州市恒诺康医药科技有限公司 Composé inhibiteur de la kinase rip1 et composition et utilisation associées
US20230060797A1 (en) * 2021-09-02 2023-03-02 Jcr Pharmaceuticals Co., Ltd. Therapeutic compound for neuronal ceroid lipofuscinosis
KR20230100646A (ko) 2021-12-24 2023-07-05 제일약품주식회사 Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
EP4463229A1 (fr) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Formes cristallines de ((s)-5-benzyl-n-(5-méthyl-4-oxo-2, 3,4,5- tétrahydropyrido [3,2-b] [l,4]oxazépin-3-yl)-4h-l,2,4-triazole-3-carboxamide
EP4495119A4 (fr) 2022-03-16 2025-06-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Composé hétérocyclique fusionné, son procédé de préparation et son utilisation médicale
WO2023240379A1 (fr) * 2022-06-13 2023-12-21 南京医工医药技术有限公司 Dérivé d'imidazolinone et son utilisation
IL318203A (en) * 2022-07-12 2025-03-01 Adama Makhteshim Ltd Process for preparing modified benzamides
CN118084889B (zh) * 2024-01-16 2024-09-27 宁夏医科大学 吲哚3-芳基-5-甲酰胺类衍生物及用途
WO2025162472A1 (fr) 2024-01-31 2025-08-07 Insmed Incorporated Inhibiteurs linéaires de la dipeptidylpeptidase 1 et leurs utilisations
WO2025259779A1 (fr) * 2024-06-12 2025-12-18 Insmed Incorporated Utilisations de certains carboxamides en tant qu'inhibiteurs de dpp1
WO2026138869A1 (fr) * 2024-12-26 2026-07-02 津药药业股份有限公司 Inhibiteur de ripk1 et son utilisation
CN119684191A (zh) * 2025-01-22 2025-03-25 中国科学技术大学 一种可见光催化合成β-内酰胺和双环[2,1,1]化合物的方法
CN120329310A (zh) * 2025-04-18 2025-07-18 中国科学院成都生物研究所 一类苯并呋喃氮杂环化合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206234A (en) 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
JP4094066B2 (ja) 1996-12-06 2008-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビター
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
AU2002359476A1 (en) 2001-11-26 2003-06-10 Exelixis, Inc. MAP4Ks AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
EP1627043A4 (fr) 2002-10-23 2006-10-11 Exelixis Inc Gene mapk7 en tant que modulateur de la morphogenese de ramification, et procedes d'utilisation
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
RU2281947C1 (ru) 2005-07-05 2006-08-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения
CN101346395A (zh) 2005-12-30 2009-01-14 默克专利有限公司 阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体
JP5511379B2 (ja) 2006-07-21 2014-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｇｒｐレセプターアンタゴニスト
CA2722418C (fr) 2008-05-13 2013-09-17 Irm Llc Heterocycles fusionnes contenant de l'azote et compositions a base de ceux-ci utilisees comme inhibiteurs de kinase
JP2013523766A (ja) * 2010-03-31 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのイミダゾリル‐イミダゾール
GB201106817D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
EP2773341A2 (fr) 2011-10-21 2014-09-10 Massachusetts Eye & Ear Infirmary Compositions comprenant des inhibiteurs de la necrose, tels que des necrostatines, seuls ou en combinaison, pour la promotion de la régénération axonale et de la fonction nerveuse, ainsi pour traiter les maladies du snc
MX2015000362A (es) 2012-07-13 2015-04-14 Hoffmann La Roche Benzo(b)-azepin-2-onas antiproliferativas.
RU2015105561A (ru) 2012-08-09 2016-09-27 Ф. Хоффманн-Ля Рош Аг Замещенные гетероазепиноны
TWI648274B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 （二）
WO2014145022A1 (fr) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Inhibiteurs hybrides de la nécroptose
EP2986317A4 (fr) 2013-04-15 2016-10-05 Yeda Res & Dev Inhibition de rip kinases pour triater des maladies lysosomales
RU2017109122A (ru) * 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
KR20170004814A (ko) 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
RU2716136C2 (ru) 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
MD3316969T2 (ro) 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
AU2016370779B2 (en) 2015-12-17 2019-07-25 Astex Therapeutics Limited Quinoline-3-carboxamides as H-PGDS inhibitors
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
EP3394072A4 (fr) 2015-12-23 2019-05-29 President and Fellows of Harvard College Analogues de la cortistatine et leurs utilisations
US9815850B2 (en) * 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3781571B1 (fr) * 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG Dérivés de n-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide et composés similaires en tant qu'inhibiteurs de la kinase rip1 pour le traitement p.e. du syndrome de l'intestin irritable (sii)
ES3043457T3 (en) * 2019-09-06 2025-11-25 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
AR121717A1 (es) * 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k

Also Published As

Publication number Publication date
UA122150C2 (uk) 2020-09-25
US10988459B2 (en) 2021-04-27
KR102603915B1 (ko) 2023-11-21
ZA201707812B (en) 2024-02-28
KR20190143848A (ko) 2019-12-31
CL2017003486A1 (es) 2018-08-03
MX2021002978A (es) 2021-05-14
CN107849023A (zh) 2018-03-27
RU2716136C2 (ru) 2020-03-06
BR112018000080A2 (pt) 2018-08-28
ES2930749T3 (es) 2022-12-21
AU2019203444A1 (en) 2019-06-06
CN107849023B (zh) 2021-03-23
US20170008877A1 (en) 2017-01-12
US20220348559A1 (en) 2022-11-03
US12281101B2 (en) 2025-04-22
AU2016287581A1 (en) 2017-12-07
MA53835A (fr) 2021-08-11
HK1251899A1 (zh) 2019-04-26
AU2016287581B2 (en) 2019-06-06
PL3317269T3 (pl) 2023-01-02
CO2017013709A2 (es) 2018-03-28
JP7190471B2 (ja) 2022-12-15
IL255830A (en) 2018-01-31
IL274391B (en) 2022-02-01
RU2018104092A3 (fr) 2019-08-05
SG10201913880XA (en) 2020-03-30
WO2017004500A1 (fr) 2017-01-05
CA2988601C (fr) 2021-12-07
CR20170573A (es) 2018-02-20
TW201716394A (zh) 2017-05-16
PE20221048A1 (es) 2022-06-30
EP3317269A1 (fr) 2018-05-09
NZ770222A (en) 2024-05-31
EP3760625B1 (fr) 2024-03-27
MX380753B (es) 2025-04-01
TWI763630B (zh) 2022-05-11
CN111269221A (zh) 2020-06-12
KR20180023988A (ko) 2018-03-07
JP2018519319A (ja) 2018-07-19
CL2020003007A1 (es) 2021-10-01
TWI788830B (zh) 2023-01-01
CA3094197A1 (fr) 2017-01-05
CN112979660A (zh) 2021-06-18
EP3317269B1 (fr) 2022-09-21
NZ737297A (en) 2024-03-22
JP2021020946A (ja) 2021-02-18
PH12018500034A1 (en) 2018-07-09
MY192762A (en) 2022-09-07
AU2019203444B2 (en) 2021-01-21
CA2988601A1 (fr) 2017-01-05
WO2017004500A9 (fr) 2017-11-30
CN111269221B (zh) 2023-09-26
CA3094197C (fr) 2023-02-28
AU2021202398A1 (en) 2021-05-20
MX2017016482A (es) 2018-03-08
JP6785252B2 (ja) 2020-11-18
PE20180501A1 (es) 2018-03-09
EP3760625A1 (fr) 2021-01-06
IL274391A (en) 2020-06-30
EP3760625C0 (fr) 2024-03-27
KR102104911B1 (ko) 2020-04-28
AU2022279425A1 (en) 2023-01-19
RU2018104092A (ru) 2019-08-05
AU2016287581A9 (en) 2018-03-15
TW202130636A (zh) 2021-08-16
IL255830B (en) 2021-02-28

Similar Documents

Publication Publication Date Title
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
EP3319611A4 (fr) Oxystérols et leurs méthodes d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA43284A (fr) Composés et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP3337517A4 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
MA44526A (fr) Oxystérols et leurs méthodes d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
EP3317273A4 (fr) Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci
EP3383917A4 (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
MA44081A (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA43282A (fr) Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
MA39915B1 (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
MA42118A (fr) Benzamides substitués et leurs méthodes d'utilisation
EP3341218C0 (fr) Compositions de moulage et leurs méthodes d'utilisation
MA41642A (fr) Variants de protoxine ii et méthodes d'utilisation
MA45602A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation